Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma (MARVSmALo)
Phase I Study of Vaccine Enriched, Autologous, Activated T-Cells Redirected to the Tumor Marker GD2 in Patients With Relapsed/Refractory Melanoma
研究概览
详细说明
The rate of progression free survival at one (1) year is < 20% for patients with stage IV metastatic melanoma, despite aggressive cytotoxic chemotherapy regimens and newly approved immunomodulatory and targeted therapy. Immunotherapy seems to hold the most promise for achieving prolonged survival or even cure, therefore,efforts have focused on several different approaches. Such approaches have used tumor vaccination, adoptive transfer of tumor infiltrating lymphocytes, and even monoclonal antibodies, unconjugated or conjugated to cytokines, toxins, or radionucleotides.
The tumor-associated antigen GD2 has been noted on the surface of several tumors, most notably neuroblastoma, but is expressed on melanoma as well. Clinical studies have shown activity of a GD2-specific chimeric T-cell receptor expressed on activated, autologous, T-cells in patients with neuroblastoma. It is the investigators intention to enrich peripheral blood mononuclear cells (PBMC) of patients with stage IV metastatic melanoma with vaccine-specific T-cells through pre-harvest/ phlebotomy vaccination with common, well understood vaccines. The investigators will then modify the T-cells to attack the GD2 antigen. These tumor redirected, vaccine specific, activated T-cells will then be infused into the patient following revaccination with the common vaccines. The Investigators will monitor expansion of the modified T-cells through serial polymerase chain reaction (PCR) assays following vaccination.
The Investigators then intend to re-vaccinate with the selected vaccines one month following infusion and monitor for expansion of the modified T-cells.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Kansas
-
Fairway、Kansas、美国、66205
- KU Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Metastatic, surgically unresectable melanoma or newly diagnosed melanoma of any stage, where the patient is unable to receive or complete standard therapy
- Life expectancy of at least 12 weeks.
- Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2
Laboratory Values
- absolute neutrophil count > 500 microliters (mcL)
- platelet > 50,000 mcL
- serum aspartate aminotransferase (AST) < 5 x institutional upper limit of normal (IULN)
- total bilirubin < 3 x IULN
- serum creatinine < 3 x IULN
- Pulse oximetry of > 95% on room air.
- Must have recovered from the toxic effects of all prior chemotherapy
Exclusion Criteria:
- Patients with rapidly progressive disease.
- Patient is currently receiving any investigational drugs
- Current cardiomegaly or bilateral pulmonary infiltrates on chest radiograph, pulmonary metastatic lesions are allowed
- Patients must not have tumor in a location where enlargement could cause airway obstruction
- Patient is pregnant or lactating
- History of hypersensitivity reactions to murine protein-containing products.
- Currently receiving immunosuppressive drugs such as corticosteroids (excluding topical treatment), tacrolimus or cyclosporin
- Received any tumor vaccines within previous six weeks
- Known hypersensitivity to rat monoclonal antibodies
- History of severe allergic reaction to Hepatitis B vaccine, Polio vaccine or Tetanus, Diphtheria, Pertussis vaccine (DTP, Tdap, DT or Td).
- Allergy to baker's yeast or other components of the vaccines.
- History of allergy to the antibiotics Neomycin, Streptomycin or Polymyxin B
- History of coma, long/multiple seizures within 7 days after DTP or Tdap, unless a cause other than the vaccine was indicated.
- Melanoma involvement of the central nervous system
- Chemotherapy given within the last 28 days
- Presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:tvs-CTL Vaccine
Infusion of activated T-cells generated from a patient's own peripheral blood mononuclear cells.
|
autologous, 14g2a.zeta
chimeric receptor transduced, activated T-cells, enriched for vaccine specific cytotoxic T-lymphocytes (tvs-CTL)
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Measurement of infusion related adverse events to evaluate the safety of infused T-cells
大体时间:4 weeks
|
To evaluate the safety of autologous, receptor-transduced, activated T-cells, enriched for vaccine-specific cytotoxic T-lymphocytes (tvs-CTL)
|
4 weeks
|
PCR measurement of retroviral construct to measure persistence of infused T-cells
大体时间:4 weeks
|
To evaluate how long the infused T-cells remain in the blood stream
|
4 weeks
|
Measurement of replication competent retrovirus to evaluate the safety of infused T-cells
大体时间:4 weeks
|
To evaluate the safety of autologous, receptor-transduced, activated T-cells, enriched for vaccine-specific cytotoxic T-lymphocytes (tvs-CTL)
|
4 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
PCR measurement of retroviral construct to measure the expansion of infused T-cells
大体时间:12 months
|
To determine the expansion of infused tvs-CTL in response to repeat vaccination with previously administered vaccines
|
12 months
|
PCR measurement of retroviral construct to compare frequency of peripheral tvs-CTL population pre-infusion vs post-revaccination
大体时间:12 months
|
To compare the frequency of tvs-CTL in the peripheral blood, after revaccination, to the frequency noted in the prior study of autologous activated, CAR-transduced T-cells infused in patients with relapsed, refractory Stage IV melanoma
|
12 months
|
Imaging studies to measure tumor response
大体时间:10 weeks
|
Evaluate tumor response to infusion of tvs-CTL and repeat vaccination post-infusion.
|
10 weeks
|
合作者和调查者
调查人员
- 首席研究员:Gary Doolittle, MD、University of Kansas Medical Center
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
tvs-CTL Vaccine的临床试验
-
Catherine Bollard主动,不招人
-
Piazza della Vittoria 14 Studio Medico - Ginecologia...完全的
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy, Baylor College...完全的
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy, Baylor College...主动,不招人